This Bioforum will provide the latest insights on delivering increased speed, greater flexibility and enhanced quality while reducing the cost, and risks of navigating the evolving biopharma landscape
The approved product has an estimated market size of around US $62 million for the twelve months ending June 2022 according to IQVIA
Ascletis is China's first biotech company which has obtained IND approvals of an oral RdRp inhibitor from both China NMPA and the U.S. FDA
Lynparza is the first and only approved PARPi targeting BRCA-mutated HER2-negative high-risk early breast cancer
The decision follows authorization from the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) in May 2022.
Genentech will be granted an exclusive license to develop and commercialize the degrader worldwide, and will be fully responsible for the development and commercialization costs.
Collaboration supports multiple discovery efforts, including vaccines
The estimated capex is to the tune of Rs. 140 crore to be funded through debt and internal accrual
Collaboration focuses on developing and implementing real-world research to drive patient access to cancer medicines
Results consistent with previous trials, reinforcing benefit of Daiichi Sankyo and AstraZeneca’s ENHERTU in previously treated patients
Subscribe To Our Newsletter & Stay Updated
